FR2761689B1 - Fibre adenovirale modifiee et adenovirus cibles - Google Patents

Fibre adenovirale modifiee et adenovirus cibles

Info

Publication number
FR2761689B1
FR2761689B1 FR9704747A FR9704747A FR2761689B1 FR 2761689 B1 FR2761689 B1 FR 2761689B1 FR 9704747 A FR9704747 A FR 9704747A FR 9704747 A FR9704747 A FR 9704747A FR 2761689 B1 FR2761689 B1 FR 2761689B1
Authority
FR
France
Prior art keywords
adenovirus
fiber
adenoviral fiber
residues
modified adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9704747A
Other languages
English (en)
French (fr)
Other versions
FR2761689A1 (fr
Inventor
Valerie Legrand
Majid Mehtali
Pierre Boulanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9703987A external-priority patent/FR2761688A1/fr
Application filed by Transgene SA filed Critical Transgene SA
Priority to FR9704747A priority Critical patent/FR2761689B1/fr
Priority to JP54126098A priority patent/JP2001522236A/ja
Priority to US09/402,401 priority patent/US6569677B1/en
Priority to ES98917294T priority patent/ES2246533T3/es
Priority to AU70547/98A priority patent/AU741728B2/en
Priority to DK98917294T priority patent/DK0991763T3/da
Priority to EP98917294A priority patent/EP0991763B1/fr
Priority to AT98917294T priority patent/ATE305513T1/de
Priority to DE69831741T priority patent/DE69831741T2/de
Priority to CA002285565A priority patent/CA2285565A1/fr
Priority to PCT/FR1998/000668 priority patent/WO1998044121A1/fr
Publication of FR2761689A1 publication Critical patent/FR2761689A1/fr
Publication of FR2761689B1 publication Critical patent/FR2761689B1/fr
Application granted granted Critical
Priority to US10/402,954 priority patent/US7256036B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9704747A 1997-04-02 1997-04-17 Fibre adenovirale modifiee et adenovirus cibles Expired - Fee Related FR2761689B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR9704747A FR2761689B1 (fr) 1997-04-02 1997-04-17 Fibre adenovirale modifiee et adenovirus cibles
EP98917294A EP0991763B1 (fr) 1997-04-02 1998-04-02 Fibre adenovirale modifiee et adenovirus cibles
DE69831741T DE69831741T2 (de) 1997-04-02 1998-04-02 Modifizierte adenovirale fiber und sie enthaltende adenoviren
ES98917294T ES2246533T3 (es) 1997-04-02 1998-04-02 Fibra adenovirica modificada y adenovirus dianas.
AU70547/98A AU741728B2 (en) 1997-04-02 1998-04-02 Modified adenoviral fiber and target adenoviruses
DK98917294T DK0991763T3 (da) 1997-04-02 1998-04-02 Modificeret adenovirusfiber og måladenovirus
JP54126098A JP2001522236A (ja) 1997-04-02 1998-04-02 改変アデノウイルスファイバーおよび標的アデノウイルス
AT98917294T ATE305513T1 (de) 1997-04-02 1998-04-02 Modifizierte adenovirale fiber und sie enthaltende adenoviren
US09/402,401 US6569677B1 (en) 1997-04-02 1998-04-02 Modified adenoviral fiber and target adenoviruses
CA002285565A CA2285565A1 (fr) 1997-04-02 1998-04-02 Fibre adenovirale modifiee et adenovirus cibles
PCT/FR1998/000668 WO1998044121A1 (fr) 1997-04-02 1998-04-02 Fibre adenovirale modifiee et adenovirus cibles
US10/402,954 US7256036B2 (en) 1997-04-02 2003-04-01 Modified adenoviral fiber and target adenoviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9703987A FR2761688A1 (fr) 1997-04-02 1997-04-02 Fibre adenovirale modifiee et adenovirus cibles
FR9704747A FR2761689B1 (fr) 1997-04-02 1997-04-17 Fibre adenovirale modifiee et adenovirus cibles

Publications (2)

Publication Number Publication Date
FR2761689A1 FR2761689A1 (fr) 1998-10-09
FR2761689B1 true FR2761689B1 (fr) 1999-06-25

Family

ID=26233432

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9704747A Expired - Fee Related FR2761689B1 (fr) 1997-04-02 1997-04-17 Fibre adenovirale modifiee et adenovirus cibles

Country Status (11)

Country Link
US (2) US6569677B1 (https=)
EP (1) EP0991763B1 (https=)
JP (1) JP2001522236A (https=)
AT (1) ATE305513T1 (https=)
AU (1) AU741728B2 (https=)
CA (1) CA2285565A1 (https=)
DE (1) DE69831741T2 (https=)
DK (1) DK0991763T3 (https=)
ES (1) ES2246533T3 (https=)
FR (1) FR2761689B1 (https=)
WO (1) WO1998044121A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1020529B1 (en) * 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU783879B2 (en) * 1999-11-25 2005-12-15 Transgene S.A. Modified adenovirus fibre and uses
AU6368901A (en) * 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
AU2001283832A1 (en) * 2000-06-02 2001-12-11 Novartis Ag Adenovirus particles with mutagenized fiber proteins
US20060228334A1 (en) * 2002-07-10 2006-10-12 Manuel Rosa-Calatrava Modified adenoviral fiber with ablated to cellular receptors
US20060281090A1 (en) * 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
JP2007503843A (ja) * 2003-05-14 2007-03-01 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー アデノウイルス親和性の拡大
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
WO2005030927A2 (en) * 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US20070010016A1 (en) * 2005-03-11 2007-01-11 Mccelland Alan Gene transfer with adenoviruses having modified fiber proteins
WO2006133911A2 (en) * 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
EP1925664A1 (en) * 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
CA2837804C (en) 2011-06-15 2018-03-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
EP4485466A3 (en) 2016-08-17 2025-04-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
WO2019135816A2 (en) 2017-10-23 2019-07-11 The Broad Institute, Inc. Novel nucleic acid modifiers
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
CN113544266A (zh) 2018-12-17 2021-10-22 博德研究所 Crispr相关转座酶系统和其使用方法
MX2021007283A (es) 2018-12-18 2021-07-15 Navigo Proteins Gmbh Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
IL316038A (en) 2022-04-04 2024-11-01 Univ California Preparations and methods for genetic complementation
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025250808A1 (en) 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Anti-crispr delivery compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6133394A (en) * 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
EE9800160A (et) * 1995-11-28 1998-12-15 Genvec, Inc. Vektorid ja meetodid geenide ülekandmiseks rakkudesse
AU779892B2 (en) * 1999-08-27 2005-02-17 European Molecular Biology Laboratory Modified adenoviral fibre and uses thereof

Also Published As

Publication number Publication date
DE69831741D1 (de) 2006-02-09
US20030175243A1 (en) 2003-09-18
AU7054798A (en) 1998-10-22
ATE305513T1 (de) 2005-10-15
ES2246533T3 (es) 2006-02-16
EP0991763A1 (fr) 2000-04-12
JP2001522236A (ja) 2001-11-13
US6569677B1 (en) 2003-05-27
AU741728B2 (en) 2001-12-06
DE69831741T2 (de) 2006-07-06
CA2285565A1 (fr) 1998-10-08
DK0991763T3 (da) 2006-02-20
US7256036B2 (en) 2007-08-14
FR2761689A1 (fr) 1998-10-09
WO1998044121A1 (fr) 1998-10-08
EP0991763B1 (fr) 2005-09-28

Similar Documents

Publication Publication Date Title
FR2761689B1 (fr) Fibre adenovirale modifiee et adenovirus cibles
EP1392360A4 (en) MODIFIED ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND THEIR USES
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
WO2004098535A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
BR0016851A (pt) Proteìnas inseticidas do bacillus thuringiensis
BR0015137A (pt) Peptìdeos antigênicos de neisseria
MX9706485A (es) Metodos y composiciones para terapia de genes para tratamiento de defectos en el metabolismo de lipoproteina.
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
CA2278616A1 (en) Adenoviruses having altered hexon proteins
EP0841941A4 (en) Novel non-pyrogenic bacterial strains and their use
AR022358A1 (es) Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
DE69524740D1 (de) Thymidin-kinase-mutanten
ERIKSEN et al. Isolation and characterization of proteoglycans from human follicular fluid
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
WO2004007537A3 (en) Modified adenoviral fiber with ablated to cellular receptors
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
BR9707994A (pt) Adenovírus recombinantes defectivo composição farmacêutica utilização do adenovirus composição e processo de preparação de células t citotóxicas especificas de um antigene tumoral
NO972063L (no) Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle

Legal Events

Date Code Title Description
ST Notification of lapse